Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
JANX Quote, Financials, Valuation and Earnings
Last price:
$14.31
Seasonality move
:
51.13%
Day range:
$14.07 - $14.49
52-week range:
$13.76 - $61.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
86.77x
P/B ratio:
0.88x
Volume:
1.5M
Avg. volume:
2.6M
1-year change:
-74.51%
Market cap:
$860.7M
Revenue:
$10.6M
EPS (TTM):
-$1.68
Analysts' Opinion
-
Consensus RatingJanux Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $65.12, Janux Therapeutics, Inc. has an estimated upside of 355.05% from its current price of $14.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing -74.7% downside risk from its current price of $14.31.
Fair Value
-
According to the consensus of 16 analysts, Janux Therapeutics, Inc. has 355.05% upside to fair value with a price target of $65.12 per share.
JANX vs. S&P 500
-
Over the past 5 trading days, Janux Therapeutics, Inc. has overperformed the S&P 500 by 0.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Janux Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Janux Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Janux Therapeutics, Inc. reported revenues of $10M.
Earnings Growth
-
Janux Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Janux Therapeutics, Inc. reported earnings per share of -$0.39.
Enterprise value:
-105.6M
EV / Invested capital:
-0.11x
Price / LTM sales:
86.77x
EV / EBIT:
--
EV / Revenue:
-10.56x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
1.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.9M
Return On Assets:
-10.47%
Net Income Margin (TTM):
-1018.95%
Return On Equity:
-10.94%
Return On Invested Capital:
-10.68%
Operating Margin:
-352.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.5M | $13M | $10M | $439K | $10M | |
| Gross Profit | $6.6M | $11M | $7.9M | -$71K | $9.5M | |
| Operating Income | -$75.1M | -$86M | -$144.3M | -$35.8M | -$35.3M | |
| EBITDA | -$73.3M | -$83.9M | -$142.2M | -$35.3M | -$34.8M | |
| Diluted EPS | -$1.48 | -$1.18 | -$1.68 | -$0.51 | -$0.39 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $389.6M | $344.3M | $355.2M | $666.3M | $998.1M | |
| Total Assets | $391.1M | $375.8M | $386.9M | $695M | $1B | |
| Current Liabilities | $12.5M | $16.3M | $14.5M | $17.2M | $27.8M | |
| Total Liabilities | $14.3M | $44.2M | $37.9M | $38.9M | $48.2M | |
| Total Equity | $376.8M | $331.5M | $348.9M | $656.1M | $976.6M | |
| Total Debt | $23K | $24.1M | $23.4M | $21.7M | $20.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$52.6M | -$37M | -$70.4M | -$2.2M | -$12.9M | |
| Cash From Investing | -$53.9M | -$280.8M | -$296.6M | $12.7M | $8.3M | |
| Cash From Financing | $58.9M | $327.4M | $388.7M | $1.6M | $493K | |
| Free Cash Flow | -$56M | -$37.8M | -$71.4M | -$2.3M | -$12.9M | |
JANX
Sector
Market Cap
$860.7M
$28.1M
Price % of 52-Week High
23.23%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-26.43%
-1.49%
1-Year Price Total Return
-74.51%
-17.13%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.28
200-day SMA
Sell
Level
$25.34
Bollinger Bands (100)
Sell
Level
19.22 - 28.82
Chaikin Money Flow
Sell
Level
-47.5M
20-day SMA
Sell
Level
$18.07
Relative Strength Index (RSI14)
Sell
Level
28.97
ADX Line
Sell
Level
40.51
Williams %R
Buy
Level
-83.6795
50-day SMA
Sell
Level
$24.08
MACD (12, 26)
Sell
Level
-3.31
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-22.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (49.5218)
Buy
CA Score
(Annual)
Level (0.9793)
Buy
Beneish M-Score
(Annual)
Level (-3.3552)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.2161)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, JANX has received 15 Buy ratings 1 Hold ratings, and 0 Sell ratings. The JANX average analyst price target in the past 3 months is $65.12.
-
Where Will Janux Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Janux Therapeutics, Inc. share price will rise to $65.12 per share over the next 12 months.
-
What Do Analysts Say About Janux Therapeutics, Inc.?
Analysts are divided on their view about Janux Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Janux Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Janux Therapeutics, Inc.'s Price Target?
The price target for Janux Therapeutics, Inc. over the next 1-year time period is forecast to be $65.12 according to 16 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is JANX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Janux Therapeutics, Inc. is a Buy. 15 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JANX?
You can purchase shares of Janux Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Janux Therapeutics, Inc. shares.
-
What Is The Janux Therapeutics, Inc. Share Price Today?
Janux Therapeutics, Inc. was last trading at $14.31 per share. This represents the most recent stock quote for Janux Therapeutics, Inc.. Yesterday, Janux Therapeutics, Inc. closed at $14.31 per share.
-
How To Buy Janux Therapeutics, Inc. Stock Online?
In order to purchase Janux Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get JANX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
JANX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.20x
-0.01x
P/B ratio
0.88x
1.81x
Price / LTM sales
86.77x
1.59x
Growth Metrics
JANX
Sector
Revenue growth
2177.9%
4.62%
Earnings growth
23.68%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.61
-$0.21
Profitability
JANX
Sector
Profitability FY 2024
$8.5M
$3.6M
Return on invested capital
-10.68%
-31.84%
Return on assets
-10.47%
-27.96%
Return on equity
-10.94%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
JANX
Sector
Total cash
$989M
$26.4M
Short term investments
$594.6M
$25.7M
Total assets
$1.1B
$76.9M
Long term debt
$20.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
56
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
